Navigation Links
Effects of Parkinson's-disease mutation reversed in cells
Date:8/16/2013

UC San Francisco scientists working in the lab used a chemical found in an anti-wrinkle cream to prevent the death of nerve cells damaged by mutations that cause an inherited form of Parkinsons disease. A similar approach might ward off cell death in the brains of people afflicted with Parkinsons disease, the team suggested in a study reported online in the journal Cell on August 15.

The achievement marks a pharmacologic milestone as the first highly specific targeting of a member of an important class of enzymes called kinases to increase rather than to inhibit their activity, according to UCSF chemist Kevan Shokat, PhD, the senior scientist on the study. The research raises hope that similar pharmaceutical strategies might be used for combatting other diseases, including diabetes and cancer, he said.

Mutations that cause malfunction of the targeted enzyme, PINK1, are directly responsible for some cases of early-onset Parkinsons disease. Loss of PINK1 activity is harmful to the cells power plants, called mitochondria, best known for converting food energy into another form of chemical energy used by cells, the molecule ATP.

In Parkinsons disease, poorly performing mitochondria have been associated with the death of dopamine-producing nerve cells in a region of the brain called the substantia nigra, which plays a major role in control of movement. Loss of these cells is a hallmark of Parkinsons disease and the cause of prominent symptoms including rigidity and tremor.

A UCSF team led by Shokat, a Howard Hughes Medical Institute Investigator, used the chemical, called kinetin, to increase mutant PINK1 enzyme activity in nerve cells to near normal levels.

In light of the fact that mutations in PINK1 produce Parkinsons disease in humans, the finding that kinetin can speed mutated PINK1 activity to near normal levels raises the possibility that kinetin may be used to treat these patients, Shokat said.

The researchers also found that, in nerve cells with normal PINK1, kinetin boosted enzyme activity beyond typical levels. This finding may be relevant for the most common forms of Parkinsons disease, in which PINK1 is not mutated, because a previous study showed that similar overactivity of PINK1 can slow the development of abnormal movement in a fruit-fly model of Parkinsons disease caused by another defect. This defect is elevated production of the protein alpha-synuclein, also a cause of some inherited cases of Parkinsons disease.

The demonstration in the new study that PINK1 can be boosted in human nerve cells that lack PINK1 mutations therefore suggests that kinetin might also have therapeutic potential in common cases of Parkinsons disease in which PINK1 is not mutated, Shokat said.

Parkinsons disease is the second most common neurodegenerative disease after Alzheimers disease, and the 14th leading cause of death in the United States, according to the U.S Centers for Disease Control and Prevention. Current treatments primarily aim to boost availability of dopamine to brain regions where dopamine-producing nerve cells have been lost.

Although many drugs that inhibit the activity of kinases have been developed over the past decade, including 15 currently approved to treat cancer, Shokat said none has yet been marketed to directly boost activity of a kinase.

The breakthrough in revving up PINK1 activity pharmacologically stemmed from Shokats unconventional approach. He targeted the enzymes substrate, a molecule that binds to an enzyme and undergoes a quick chemical transformation as a result. PINK1 uses ATP as a substrate, and the chemical reaction helps PINK1 in turn drive the activation of another enzyme, called Parkin.

Both of these enzymes are among a small number that previously have been strongly linked to Parkinsons disease. PINK1 and Parkin act together to monitor the health of mitochondria, and help trigger repair or disposal of damaged mitochondria within the cells, thereby promoting cell survival.

Therapeutic approaches for enhancing the activity of PINK1 had not been considered, because scientists had not conceived of the idea of developing a new substrate for the enzyme, Shokat said.

We found that a small molecule, called KTP, speeds chemical reactions catalyzed by PINK1 better than ATP, the natural substrate. That kind of better-than-natural response is essentially unheard of.

KTP is too big to fit into other kinases, Shokat said, but PINK1 has a larger ATP pocket to hold KTP.

After discovering the potential of KTP, the researchers then determined that kinetin is converted to KTP within cells. Experimentally, kinetin, which can cross blood vessels to get into the brain, has been given by mouth to treat a rare, genetic, neurological disease called familial dysautonomia.


'/>"/>

Contact: Jeffrey Norris
jeff.norris@ucsf.edu
415-502-6397
University of California - San Francisco
Source:Eurekalert

Related medicine news :

1. Mirena Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in New Jersey Mirena Side Effects Litigation
2. Researcher awarded $1.8 million grant to study gender differences in antidepressant effects
3. Mental Health Watchdog Launches Psychiatric Drug Side Effects Database—Search All Drug Regulatory Agency Warnings, Studies & Adverse Reactions Reports
4. Pradaxa Lawsuit Lawyers at Wright & Schulte LLC Disturbed by New Study Finding that Pradaxa Users Face Significantly Higher Risk of Bleeding Side-Effects
5. Research shows negative effects of half-siblings
6. Latest Yaz, Yasmin Lawsuits Alleging Blood-Clotting Side Effects: Resource4thePeople Reports Consolidated Cases Continue to Be Opened, Settled and Dismissed
7. Necrostatin-1 counteracts aluminums neurotoxic effects
8. Understanding the effects of genes on human traits
9. New Update on Alleged Transvaginal Mesh Complications Lawsuits: First Federal Trial Involving Allegations of Serious Side Effects from C.R. Bard Mesh Scheduled to Begin
10. Frequent Urination can be Terminated by Taking Herbal Medicine with No Side Effects, Highlights Wuhan Dr. Lee's TCM Clinic
11. A lifespan-extending drug has limited effects on aging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... ... May 31, 2016 , ... Presence Technology ... has been included by Gartner, Inc. in the Contact Center Infrastructure Magic Quadrant ... Center Infrastructure technologies, some of which include: Computer-telephony integration (CTI)/Web services interfaces, ...
(Date:5/31/2016)... Beach, Florida (PRWEB) , ... May 31, 2016 ... ... to Jay Butch of CertainTeed Corporation, he knew it was something that contractors ... as state-of-the-art and cutting-edge as it gets,” says Butch, CertainTeed’s Director of Contractor ...
(Date:5/31/2016)... Switzerland (PRWEB) , ... May 31, 2016 , ... The ... this model in their laboratories as well. However, laboratories have different challenges compared to ... benefits of lean operations in the lab, METTLER TOLEDO has developed the Lean ...
(Date:5/31/2016)... ... 2016 , ... Spectrum Aquatics has launched a brand new ADA pool lift, ... with the user in mind. , “Over the last two years our key customers ... 400 lbs lift is a necessary requirement for certain facilities with specific needs,” said ...
(Date:5/31/2016)... ... ... a recent interview on The Greenburgh Report radio show hosted by Greenburgh, NY Town ... leading medical insurance advocate Adria Goldman Gross discussed several eye-opening issues that have combined ... the interview with Mr. Feiner that aired on May 7, 2016, Ms. Gross, the ...
Breaking Medicine News(10 mins):
(Date:5/30/2016)... 30, 2016 According ... Biometrics Market by Technology (Single-factor (Fingerprint, Face, ... Application (Workforce Management), End User (Hospitals, Healthcare ... by MarketsandMarkets, the market is projected to ... USD 1,182.6 Million by 2016, at a ...
(Date:5/30/2016)... - DCGI grants limited approval to market Stempeucel® product for ... Stempeucel® becomes 5th off-the-shelf Stem cell product to be approved by ... Disease (also known as Thromboangiitis Obliterans) is a major unmet medical ... - Prevalence of Buerger,s Disease is estimated to be 1,000,000 in ... the European Community & USA ...
(Date:5/27/2016)... LabStyle Innovations Corp . ( ... today announced that the Company,s Chief Financial Officer, Zvi ... held June 1-2 in New York, NY ... in Los Angeles, CA. ... operational milestones, including the U.S. FDA Clearance and commercial launch ...
Breaking Medicine Technology: